18 Oct 2018 IMRALDI™, Biogen’s Adalimumab Biosimilar Referencing Humira®, Is Launched in the European Union
18 Oct 2018 AbbVie Announces Global Resolution of HUMIRA® (adalimumab) Patent Disputes with Fresenius Kabi
18 Oct 2018 ASLAN Pharmaceuticals Enrolls First Subject in Phase 1 Study for ASLAN004 in Atopic Dermatitis
16 Oct 2018 Five Prime Therapeutics Initiates Patient Dosing in The Dose Exploration Cohort of Its Phase 1 Trial of Novel First-in-Class B7-H4 Antibody FPA150
16 Oct 2018 Alphamab Oncology's HER2 bispecific antibody KN026 gained US IND approval; phase I clinical trial started in China
16 Oct 2018 Innovent Receives IND Approval to Initiate Clinical Trials in China with Sintilimab in Combination with its Biosimilar to Bevacizumab
16 Oct 2018 CStone Receives U.S. IND Approval for PD-L1 Antibody CS1001
16 Oct 2018 Amgen Launches AMGEVITA™ (Biosimilar Adalimumab) In Markets Across Europe
16 Oct 2018 Dupixent® (dupilumab) showed positive topline results in two Phase 3 trials of patients with chronic rhinosinusitis with nasal polyps
15 Oct 2018 Chugai Presents Results from Phase III Study of Satralizumab in NMOSD at ECTRIMS 2018
15 Oct 2018 Genentech’s Kadcyla Reduced the Risk of Disease Recurring in People With HER2-Positive Early Breast Cancer With Residual Disease After Neoadjuvant Treatment
14 Oct 2018 Sandoz announces global resolution of biosimilar adalimumab patent disputes, securing patient access
14 Oct 2018 Bristol-Myers Squibb Announces Phase 3 CheckMate -331 Study Does Not Meet Primary Endpoint of Overall Survival with Opdivo Versus Chemotherapy in Patients with Previously Treated Relapsed Small Cell Lung Cancer
11 Oct 2018 ProMIS Neurosciences Identifies Novel Antibody Drug Candidates for Parkinson's Disease
11 Oct 2018 Bristol-Myers Squibb and Compugen Announce Clinical Collaboration to Evaluate Therapeutic Regimen in Advanced Solid Tumors
11 Oct 2018 Celltrion and Teva Announce FDA Oncologic Drugs Advisory Committee Recommends Approval of Celltrion BLA for CT-P10, a Proposed Rituximab Biosimilar
10 Oct 2018 Alphamab Oncology's first-in-class PD-L1 - CTLA-4 bispecific antibody enters clinical trial
10 Oct 2018 Novartis analysis shows crizanlizumab (SEG101) increased the number of patients free of sickle cell pain crises vs placebo during SUSTAIN study
09 Oct 2018 Affimed Places AFM11 (CD19/CD3-Targeting T cell Engager) Phase 1 Program on Clinical Hold
06 Oct 2018 Xencor Announces Topline Results from Phase 2 Study of XmAb®5871 in Systemic Lupus Erythematosus and Selection of Late-Breaking Abstract for Presentation at the 2018 ACR Annual Meeting
05 Oct 2018 Horizon Pharma plc Announces Presentation of Data From 48 Week Off-Therapy Follow-Up to the Phase 2 Trial of Teprotumumab
05 Oct 2018 Chugai's HEMLIBRA® Receives Regulatory Approval from U.S. FDA for Hemophilia A Without Inhibitors
02 Oct 2018 Five Prime Therapeutics and Zai Lab Dosed First Patient in Phase 3, Global Registrational Trial of Bemarituzumab in Front-Line Advanced Gastric and Gastroesophageal Junction Cancers
02 Oct 2018 PharmAbcine Announces FDA Accepts IND Application of TTAC-0001 for the Treatment of Recurrent Glioblastoma
02 Oct 2018 ADMA Biologics Resubmits Biologics License Application for RI-002

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2017 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up